This is the authors' abstract. We don't add key points for this paper.
The best catalyst from a chemical perspective is not necessarily the best catalyst from an overall economic perspective. In competing approaches to candoxatril the most selective catalyst for the asymmetric hydrogenation (see scheme) was not the one ultimately chosen. The constraints of the pharmaceutical industry are discussed with regard to the application of asymmetric catalysis to the large-scale synthesis of drug candidates and commercial drugs.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hawkins et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: